1. Despite the recent surge in gold, the probability of a sustained pullback to $2,300 has increased due to technical developments in related macro markets. 2. The USD and bond yields are trading at key support levels, with the market aggressively pricing in rate cuts. 3. Cyclical commodity sectors like energy, base metals, and agriculture show potential for outperformance, suggesting disinflation fears may be overdone.

1. The author has warned about the risks of owning Direxion Daily Semiconductor Bull 3x Shares ETF (SOXL) since April. 2. SOXL has dropped 25% since the original article, with a potential for another 50% to 80% loss. 3. The daily rebalancing feature and high holding costs make long-term gains unlikely.

1. Merck's 15% decline in July presents an intermediate to long-term buying opportunity for investors. 2. Long-term trend lines and Bollinger Bands suggest strong support at $110, with an expected return to July's high of $133. 3. Sentiment indicators show a majority of investors expect lower prices, which is a positive sign for higher prices. 4. RSI levels indicate Merck is oversold for the intermediate term, suggesting a significant rally. 5. If the price target of $133 is reached, the article will reassess whether it's forming a double top or going higher.

1. Amazon's revenue growth remains steady, with a positive outlook for AWS offset by slower e-commerce growth due to a weaker consumer environment. 2. Despite a rare EBIT margin guidance disappointment, potential easing of global container freight rates and internal cost-saving initiatives offer margin expansion opportunities. 3. The stock's technical pullback creates a favorable entry point for investors, suggesting a potential for multiple expansion and outperformance.

1. The S&P 500 has declined for three consecutive weeks, nearing the 5265 target. 2. Technical analysis suggests a potential collapse, but the author is prepared to bet against it under favorable conditions. 3. The article provides a detailed technical outlook and conditions for potential buying opportunities.

1. Pfizer's stock is trading above its 30-week EMA, indicating a bullish trend. 2. The company has shown increasing momentum and improving relative strength. 3. Smart money buying and volume spikes suggest a bullish outlook for Pfizer stock.